Investors focus is likely to be on the performance of Lannett Company, Inc.’s LCI anti-psychosis and cardiovascular drugs when it reports fiscal first-quarter 2020 results.
Lannett’s shares have rallied 147.2% so far this year compared with the industry’s increase of 0.5%.
Factors at Play
Lannett’s generic product launches since 2018 have driven net sales and the trend most likely continued in the soon-to-be reported quarter. In fact, anti-psychosis and cardiovascular drugs in the company’s generic portfolio witnessed strong sales growth in the fiscal fourth quarter of 2019. We expect this trend to have continued in the fiscal first quarter of 2020.
The Zacks Consensus Estimates for sales of anti-psychosis and cardiovascular drugs stands at $18 million and $25 million, respectively.
In May and June, the company launched generic versions of two major attention deficit hyperactivity disorder drugs namely J&J’s JNJ Concerta and Teva Pharmaceutical’s TEVA Adderall. Launch of these two generic drugs along with a generic version of Aspirin are likely to have resulted in significant sales for Lannett.
Restructuring initiatives and reduction in outstanding loans is likely to have benefited Lannett’s bottom line in the first quarter of 2020. However, continued launches and research activities might have driven operating expenses higher.
Our proven model does not conclusively predict an earnings beat for Lannett in this reporting cycle. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here as you will see below.
Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate is -1.64%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Lannett sports a Zacks Rank #1.
Lannett Co Inc Price and Consensus
Lannett Co Inc price-consensus-chart | Lannett Co Inc Quote
A Stock That Warrants a Look
Here is a biotech stock that you may want to consider, as our model shows that it has the right combination of elements to post an earnings beat in its upcoming release.
Incyte Corporation INCY has an Earnings ESP of +1.15% and a Zacks Rank #1. The company is scheduled to release third-quarter results on Oct 29. You can see the complete list of today’s Zacks #1 Rank stocks here.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Johnson & Johnson (JNJ) : Free Stock Analysis Report
Incyte Corporation (INCY) : Free Stock Analysis Report
Lannett Co Inc (LCI) : Free Stock Analysis Report
Teva Pharmaceutical Industries Ltd. (TEVA) : Free Stock Analysis Report
To read this article on Zacks.com click here.